The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwMyeloma 2016 | Venetoclax for multiple myeloma – mechanism of action and next steps
Lawrence Boise, PhD, from the Winship Cancer Institute, Atlanta, GA, discusses the mechanism of action of venetoclax and next steps for the drug in multiple myeloma (MM). Venetoclax is an inhibitor of BCL-2 and has recently been approved for the treatment of chronic lymphocytic leukemia (CLL). According to Prof Boise, only a small fraction of multiple myeloma patients appear to be sensitive to venetoclax and the next step is to find a marker that can identify those patients. Another area of research concerns drug combinations, i.e. finding drugs such as dexamethasone, that can be combined with venetoclax.
Recorded at the Myeloma 2016 meeting held in Boston, MA.
